Active substance
Lisinopril
- SFDA 34
- US FDA 23
- Health Canada 15
- US price lines 8
- NHS prices 5
- Safety 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| LINOPRIL 10MG TABLET | 10 mg | Tablet · Oral use | 28 Blister | SAR 26.00 | Generic · Prescription | Pharma International Co. | Valid |
| LINOPRIL 20MG TABLET | 20 mg | Tablet · Oral use | 28 Blister | SAR 41.25 | Generic · Prescription | Pharma International Co. | Valid |
| LINOPRIL 5MG TABLET | 5 mg | Tablet · Oral use | 28 Blister | SAR 15.80 | Generic · Prescription | Pharma International Co. | Valid |
| LISINO 10MG TABLETS | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 27.85 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| LISINO 20MG TABLETS | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 47.50 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| LISINO 5MG TABLET | 5 mg | Film-coated tablet · Oral use | 30 Blister | SAR 16.85 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| OMACE 10MG TABLETS | 10 mg | Tablet · Oral use | 28 Blister | SAR 26.00 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| OMACE 20MG TABLETS | 20 mg | Tablet · Oral use | 28 Blister | SAR 44.35 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| OMACE 5MG TABLETS | 5 mg | Tablet · Oral use | 28 Blister | SAR 15.80 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| Omace | 20 mg | Tablet · Oral use | 840 Blister | SAR 1279.60 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| Omace | 10 mg | Tablet · Oral use | 840 Blister | SAR 779.75 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| Omace | 5 mg | Tablet · Oral use | 840 Blister | SAR 474.00 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| ZESTRIL 10MG TAB | 10 mg | Tablet · Oral use | 28 Blister | SAR 26.00 | NCE · Prescription | Atnahs Pharma UK Limited | Valid |
| ZESTRIL 20MG TAB | 20 mg | Tablet · Oral use | 28 Blister | SAR 44.35 | NCE · Prescription | Atnahs Pharma UK Limited | Valid |
| ZESTRIL 5MG TAB | 5 mg | Tablet · Oral use | 28 Blister | SAR 15.80 | NCE · Prescription | Atnahs Pharma UK Limited | Valid |
| ZINOPRIL | 5 mg | Tablet · Oral use | 238 Blister | SAR 134.30 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ZINOPRIL | 10 mg | Tablet · Oral use | 238 Blister | SAR 221.00 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ZINOPRIL | 20 mg | Tablet · Oral use | 238 Blister | SAR 376.95 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ZINOPRIL 10 MG TAB | 10 mg | Tablet · Oral use | 28 Blister | SAR 26.00 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ZINOPRIL 20 MG TABLET | 20 mg | Tablet · Oral use | 28 Blister | SAR 44.35 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ZINOPRIL 5 MG TABLETS | 5 mg | Tablet · Oral use | 28 Blister | SAR 15.80 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| LISDENE 10MG TABLETS | 10 mg | Tablet · Oral use | 28 Blister | SAR 25.75 | Generic · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| LISDENE 20MG TABLET | 20 mg | Tablet · Oral use | 28 Blister | SAR 40.45 | Generic · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| LISDENE 5MG TABLETS | 5 mg | Tablet · Oral use | 28 Blister | SAR 16.25 | Generic · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| LISOPHAR 10MG TABLETS | 10 mg | Tablet · Oral use | 30 Blister | SAR 25.70 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
9 more — full table
Indications — CHI Daman Drug Formulary
CARDIOMYOPATHY; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; HYPERTENSION; NON-ST WAVE ELEVATED MYOCARDIAL INFARCTION (NSTEMI); SICKLE CELL DISEASE - ALBUMINURIA MANAGEMENT; ST-WAVE ELEVATED MYOCARDIAL INFARCTION (STEMI); SYSTEMIC LUPUS ERYTHEMATOSUS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZESTRIL | 5MG; 10MG; 20MG; 40MG; 2.5MG; 30MG | tablet · oral | TWI PHARMS | Prescription | 19 May 1988 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | PRINSTON INC | Prescription | 1 Jul 2002 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | ANNORA PHARMA | Prescription | 1 Jul 2002 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 40MG; 30MG | tablet · oral | SUN PHARM INDS LTD | Prescription | 1 Jul 2002 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | CHARTWELL RX | Prescription | 1 Jul 2002 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | WATSON LABS | Prescription | 1 Jul 2002 |
| LISINOPRIL | 20MG; 30MG; 40MG; 2.5MG; 5MG; 10MG | tablet · oral | PRINSTON INC | Prescription | 1 Jul 2002 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | COREPHARMA | Prescription | 30 Sep 2002 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | LUPIN | Prescription | 9 Sep 2005 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | AUROBINDO | Prescription | 22 Feb 2006 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | WOCKHARDT BIO AG | Prescription | 19 Apr 2007 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | INVAGEN PHARMS | Prescription | 29 Oct 2013 |
| QBRELIS | 1MG/ML | solution · oral | AZURITY | Prescription | 29 Jul 2016 |
| LISINOPRIL | 2.5MG; 5MG; 10MG | tablet · oral | SCIEGEN PHARMS | Prescription | 15 Sep 2020 |
| LISINOPRIL | 20MG; 30MG; 40MG | tablet · oral | SCIEGEN PHARMS | Prescription | 4 Mar 2021 |
| LISINOPRIL | 1MG/ML | solution · oral | ANNORA PHARMA | Prescription | 20 Aug 2026 |
| PRINIVIL | 5MG; 10MG; 20MG; 40MG; 2.5MG | tablet · oral | MERCK | Discontinued | 29 Dec 1987 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | HERITAGE PHARMA | Discontinued | 1 Jul 2002 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | TEVA | Discontinued | 1 Jul 2002 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | RISING | Discontinued | 1 Jul 2002 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 40MG; 30MG | tablet · oral | HIKMA INTL PHARMS | Discontinued | 1 Jul 2002 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | STRIDES PHARMA | Discontinued | 1 Jul 2002 |
| LISINOPRIL | 2.5MG; 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | ACCORD HLTHCARE | Discontinued | 30 Jul 2013 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AURO-LISINOPRIL | 02394472 | 5 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-LISINOPRIL | 02394480 | 10 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-LISINOPRIL | 02394499 | 20 MG | TABLET · ORAL | AURO PHARMA INC |
| LISINOPRIL (TYPE Z) | 02525186 | 5 MG | TABLET · ORAL | SANIS HEALTH INC |
| LISINOPRIL (TYPE Z) | 02525194 | 10 MG | TABLET · ORAL | SANIS HEALTH INC |
| LISINOPRIL (TYPE Z) | 02525208 | 20 MG | TABLET · ORAL | SANIS HEALTH INC |
| LISINOPRIL TABLETS | 02554488 | 5 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| LISINOPRIL TABLETS | 02554496 | 10 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| LISINOPRIL TABLETS | 02554518 | 20 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| TEVA-LISINOPRIL (TYPE Z) | 02285118 | 5 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-LISINOPRIL (TYPE Z) | 02285126 | 10 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-LISINOPRIL (TYPE Z) | 02285134 | 20 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ZESTRIL | 02049333 | 5 MG | TABLET · ORAL | SEARCHLIGHT PHARMA INC |
| ZESTRIL | 02049376 | 10 MG | TABLET · ORAL | SEARCHLIGHT PHARMA INC |
| ZESTRIL | 02049384 | 20 MG | TABLET · ORAL | SEARCHLIGHT PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LISINOPRIL 10 MG TABLET | $0.01815 | per EA | 23 Sep 2026 |
| US NADAC | LISINOPRIL 2.5 MG TABLET | $0.01404 | per EA | 23 Sep 2026 |
| US NADAC | LISINOPRIL 20 MG TABLET | $0.02536 | per EA | 23 Sep 2026 |
| US NADAC | LISINOPRIL 30 MG TABLET | $0.052 | per EA | 23 Sep 2026 |
| US NADAC | LISINOPRIL 40 MG TABLET | $0.04625 | per EA | 23 Sep 2026 |
| US NADAC | LISINOPRIL 5 MG TABLET | $0.01433 | per EA | 23 Sep 2026 |
| US NADAC | QBRELIS 1 MG/ML SOLUTION | $4.49739 | per ML | 23 Sep 2026 |
| US NADAC | ZESTRIL 10 MG TABLET | $12.52442 | per EA | 18 Mar 2026 |
| NHS Drug Tariff | Lisinopril 10mg tablets | £0.90 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lisinopril 2.5mg tablets | £0.73 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lisinopril 20mg tablets | £1.45 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lisinopril 5mg tablets | £0.81 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lisinopril 5mg/5ml oral solution sugar free | £235.77 | 150 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 9 Nov 2021 PRINIVIL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Drug Interactions; Use in Specific Populations - US FDA 20 Aug 2020 ZESTORETIC — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 28 Jul 2017 QBRELIS — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Drug Interactions - US FDA 21 Jul 2017 ZESTRIL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Drug Interactions; Use in Specific Populations
Combinations containing Lisinopril
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.